Loading...
Loading...
India's magnesium imports from GERMANY total $4.4M across 55 shipments from 5 foreign suppliers. PEKANA NATURHEILMITTEL GMBH leads with $4.3M in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include GERMAN HOMOEOPATHIC DISTRIBUTORS PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for magnesium โ a diversified sourcing base with multiple active suppliers from GERMANY.

PEKANA NATURHEILMITTEL GMBH is the leading Magnesium supplier from GERMANY to India, with import value of $4.3M across 29 shipments. The top 5 suppliers โ PEKANA NATURHEILMITTEL GMBH, DEUTSCHE HOMOOPATHIE-UNION, PRIVAPOSERVICES GMBH, ILAPO, PHARMAQUELLE LLC C/O LLAPO โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | PEKANA NATURHEILMITTEL GMBH | $4.3M | 29 | 99.1% |
| 2 | DEUTSCHE HOMOOPATHIE-UNION | $27.7K | 19 | 0.6% |
| 3 | PRIVAPOSERVICES GMBH | $8.1K | 4 | 0.2% |
| 4 | ILAPO | $4.2K | 2 | 0.1% |
| 5 | PHARMAQUELLE LLC C/O LLAPO | $211 | 1 | 0.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | GERMAN HOMOEOPATHIC DISTRIBUTORS PRIVATE LIMITED | $4.3M | 29 | 99.1% |
| 2 | DR WILLMAR SCHWABE INDIA PRIVATE LIMITED | $27.7K | 19 | 0.6% |
| 3 | AUROBINDO PHARMA LTD |
GERMANY โ India trade corridor intelligence
As of April 2026, the Germany to India pharmaceutical trade corridor remains active, with no significant disruptions reported. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion. Freight rates have stabilized, and the exchange rate between the Indian Rupee (INR) and the Euro remains favorable for importers. These factors contribute to a stable and predictable import environment for pharmaceutical products.
The Indian government's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce import dependency. While this initiative encourages local production, it may impact the volume of finished pharmaceutical formulation imports, including those from Germany. However, the demand for specialized and patented magnesium formulations may continue to necessitate imports, even as domestic capabilities expand.
India and Germany maintain strong trade relations, with ongoing negotiations to enhance cooperation in various sectors, including pharmaceuticals. Discussions focus on mutual recognition of Good Manufacturing Practices (GMP), which would facilitate smoother trade and regulatory processes. These efforts aim to strengthen bilateral ties and promote the exchange of high-quality pharmaceutical products between the two nations.
| $4.5K |
| 2 |
| 0.1% |
| 4 | HETERO LABS LIMITED | $4.2K | 2 | 0.1% |
| 5 | AUROBINDO PHARMA LIMITED | $3.7K | 2 | 0.1% |
| 6 | UNIZA LIFECARE PRIVATE LIMITED | $211 | 1 | 0.0% |
To estimate the landed cost of importing finished magnesium formulations from Germany to India, consider the following components:
By summing these components, importers can calculate the total landed cost per unit, which is crucial for pricing and profitability assessments.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing magnesium into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organisation (CDSCO) mandates that all imported pharmaceutical products possess a valid import license issued under Form 10 of the Drugs and Cosmetics Rules, 1945. Additionally, each product must be registered with CDSCO under Form 41, which serves as authorization for importation. Importers must also obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) to facilitate customs clearance. The registration process involves submitting comprehensive documentation, including a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificates, and stability data. The timeline for obtaining CDSCO approval can vary, but it typically ranges from several months to over a year, depending on the completeness of the application and the regulatory workload.
Imported pharmaceutical formulations containing magnesium are subject to quality testing by CDSCO-approved laboratories to ensure compliance with Indian standards. Each batch must undergo testing, and a Certificate of Analysis (CoA) must be provided, confirming that the product meets the specifications outlined in the Indian Pharmacopoeia. Stability data, particularly for ICH Zone IV conditions, is required to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the products. If a batch fails to meet the required standards, it may be rejected, leading to potential delays or the need for re-exportation.
Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Additionally, bilateral agreements between India and Germany have streamlined the import process, including mutual recognition of Good Manufacturing Practices (GMP), which facilitates smoother trade relations. These developments aim to balance the promotion of domestic industry with the need for high-quality imported pharmaceuticals.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 17.10%
India imports finished magnesium formulations to meet the demand for specific dosage forms and patented or branded products not available domestically. The domestic pharmaceutical industry may lack the capacity to produce certain specialized magnesium formulations, leading to reliance on imports. The market size for magnesium formulations in India is substantial, with a total export market of $361.3 million across 669 exporters to 149 countries. This indicates a significant demand for magnesium-based pharmaceutical products within the country.
The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Integrated Goods and Services Tax (IGST) of 12%, and a Social Welfare Surcharge (SWS) of 10%, totaling 17.10%. These duties are applicable to imports from Germany, as there are no specific exemptions or preferential rates for German-origin products under the MFN tariff. Importers should account for these duties when calculating the total landed cost of imported goods.
India sources finished magnesium formulations from Germany due to the country's competitive advantages, including patented formulations, specialized dosage forms, and high-quality manufacturing standards. German manufacturers are known for their innovation and adherence to stringent quality controls, making them preferred suppliers for specific magnesium formulations. While other countries like China, the United States, and other European nations also supply magnesium formulations, Germany's reputation for quality and reliability positions it favorably in the Indian market.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports magnesium formulations from Germany due to the availability of patented products, specialized dosage forms, and high-quality manufacturing standards that may not be met by domestic producers. German manufacturers offer formulations containing magnesium that are unique or not produced locally, fulfilling specific market needs in India.
When compared to other sources like China, the United States, and other European countries, Germany offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. German pharmaceutical products are known for their adherence to stringent quality controls and innovative formulations, making them a preferred choice for Indian importers seeking high-quality magnesium formulations.
Importing finished magnesium formulations from Germany involves certain risks, including dependency on a single source, currency fluctuations, regulatory changes, and potential shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, monitoring currency exchange rates, staying updated on regulatory developments, and maintaining buffer stocks to manage supply chain uncertainties.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Magnesium suppliers from GERMANY to India include PEKANA NATURHEILMITTEL GMBH, DEUTSCHE HOMOOPATHIE-UNION, PRIVAPOSERVICES GMBH. The leading supplier is PEKANA NATURHEILMITTEL GMBH with import value of $4.3M USD across 29 shipments. India imported Magnesium worth $4.4M USD from GERMANY in total across 55 shipments.
India imported Magnesium worth $4.4M USD from GERMANY across 55 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Magnesium sourced from GERMANY include GERMAN HOMOEOPATHIC DISTRIBUTORS PRIVATE LIMITED, DR WILLMAR SCHWABE INDIA PRIVATE LIMITED, AUROBINDO PHARMA LTD. The largest buyer is GERMAN HOMOEOPATHIC DISTRIBUTORS PRIVATE LIMITED with $4.3M in imports across 29 shipments.
The total value of Magnesium imports from GERMANY to India is $4.4M USD, across 55 shipments and 5 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
55 Verified Shipments
5 suppliers, 6 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists